Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients.
Neoprobe, under license from the University of California San Diego Cancer Center, is developing 99mTc-DTPA-mannosyl-dextran (Lymphoseek) as a potential agent for imaging lymph nodes in patients undergoing treatment for breast cancer and melanoma. Phase II trials of Lymphoseek were initiated in mid 2006.
de Paulis
Tomas
T
Lntdp@earthlink.net
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D003287:Contrast Media / Q000009:adverse effects / Q000493:pharmacokinetics*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D013329:Structure-Activity Relationship
D003287:Contrast Media